Longtime biotech leader Ed Kaye is chasing another rare-disease drug for ailing kids

The CEO of Stoke Therapeutics began his career treating rare pediatric genetic diseases. From there he joined Genzyme, then Sarepta Therapeutics before assuming his current role in 2018.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *